Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.

Liang, T Jake; Law, John L M; Pietschmann, Thomas; Ray, Stuart C; Bukh, Jens; Bull, Rowena; Chung, Raymond T; Tyrrell, D Lorne; Houghton, Michael; Rice, Charles M

Liang, T Jake; Law, John L M; Pietschmann, Thomas; Ray, Stuart C; Bukh, Jens; Bull, Rowena; Chung, Raymond T; Tyrrell, D Lorne; Houghton, Michael; Rice, Charles M.

Affiliation

Liang TJ; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Law JLM; Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
Pietschmann T; Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany.
Ray SC; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Bukh J; Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital; Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Bull R; Liver Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Chung RT; School of Biomedical Sciences and The Kirby Institute, Medicine and Health, University of New South Wales, Sydney, Australia.
Tyrrell DL; Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
Houghton M; Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
Rice CM; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.

Clin Infect Dis ; 77(Suppl 3): S257-S261, 2023 08 14.

Article de En | MEDLINE | ID: mdl-37579208

ABSTRACT

ABSTRACT

For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

Sujet(s)
Mots clés

acute hepatitis; risk-benefit analysis; treatment; vaccine development

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Hépatite C / Hepacivirus Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Clin Infect Dis Sujet du journal: DOENCAS TRANSMISSIVEIS Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google